Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Circ Heart Fail. 2019 Apr;12(4):e005565. doi: 10.1161/CIRCHEARTFAILURE.118.005565

Figure 4: Treatment of CF with exogenous ANF causes dose-dependent decreases in myofibroblast gene expression.

Figure 4:

A-B. Pre-treatment of neonatal mouse CF with ANF significantly and dose-dependently attenuates TGF-β1 dependent induction of Acta2 (A) and Postn (B) gene expression. C. ANF pre-treatment trends toward recovery of Tcf21 expression. For all experiments, n = 3 each condition. One-way ANOVA with repeated measures (ANF concentration). * = p < 0.05 relative to 0ng/mL TGF-β1 / 0 M ANF. & = p < 0.05 relative to 10ng/mL TGF-β1 / 0 M ANF. D. ANF pre-treatment does not significantly alter cell cycle gene expression in neonatal CF that are stimulated with TGF-β1 alone. One-way ANOVA for each gene with repeated measures (concentration). * = p < 0.05 relative to vehicle control. E. ANF significantly ablates TGF-β1 / AngII-induced changes in cell cycle gene expression that are associated with proliferation. Two-way ANOVA with Tukey’s multiple comparisons test. * = p < 0.05 compared to vehicle control. & = p < 0.05 relative to TGF-β1/AngII condition.